Literature DB >> 15265789

Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells.

Xia Zhang1, Maria Cecilia Rodriguez-Galán, Jeff J Subleski, John R Ortaldo, Deborah L Hodge, Ji-Ming Wang, Osamu Shimozato, Della A Reynolds, Howard A Young.   

Abstract

Interferon-gamma (IFN-gamma) production and cytolytic activity are 2 major biologic functions of natural killer (NK) cells that are important for innate immunity. We demonstrate here that these functions are compromised in human NK cells treated with peroxisome proliferator-activated-gamma (PPAR-gamma) ligands via both PPAR-gamma-dependent and -independent pathways due to variation in PPAR-gamma expression. In PPAR-gamma-null NK cells, 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)), a natural PPAR-gamma ligand, reduces IFN-gamma production that can be reversed by MG132 and/or chloroquine, and it inhibits cytolytic activity of NK cells through reduction of both conjugate formation and CD69 expression. In PPARgamma-positive NK cells, PPAR-gamma activation by 15d-PGJ(2) and ciglitazone (a synthetic ligand) leads to reduction in both mRNA and protein levels of IFN-gamma. Overexpression of PPAR-gamma in PPAR-gamma-null NK cells reduces IFN-gamma gene expression. However, PPAR-gamma expression and activation has no effect on NK cell cytolytic activity. In addition, 15d-PGJ(2) but not ciglitazone reduces expression of CD69 in human NK cells, whereas CD44 expression is not affected. These results reveal novel pathways regulating NK cell biologic functions and provide a basis for the design of therapeutic agents that can regulate the function of NK cells within the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265789     DOI: 10.1182/blood-2004-02-0664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Minireview: Challenges and opportunities in development of PPAR agonists.

Authors:  Matthew B Wright; Michele Bortolini; Moh Tadayyon; Martin Bopst
Journal:  Mol Endocrinol       Date:  2014-08-22

Review 2.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

3.  Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.

Authors:  H S Madapura; N Nagy; D Ujvari; T Kallas; M C L Kröhnke; S Amu; M Björkholm; L Stenke; P K Mandal; J S McMurray; M Keszei; L S Westerberg; H Cheng; F Xue; G Klein; E Klein; D Salamon
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice.

Authors:  Hye-Youn Cho; Wesley Gladwell; Xuting Wang; Brian Chorley; Douglas Bell; Sekhar P Reddy; Steven R Kleeberger
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

Review 5.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

6.  Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword.

Authors:  Howard Li; Mary C M Weiser-Evans; Raphael Nemenoff
Journal:  PPAR Res       Date:  2012-08-12       Impact factor: 4.964

Review 7.  PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation.

Authors:  Tamas Varga; Zsolt Czimmerer; Laszlo Nagy
Journal:  Biochim Biophys Acta       Date:  2011-03-05

8.  The modulation of PPARγ1 and PPARγ2 mRNA expression by ciglitazone in CD3/CD28-activated naïve and memory CD4+ T cells.

Authors:  Mohd Nor Norazmi; Rafeezul Mohamed; Asma Abdullah Nurul; Nik Soriani Yaacob
Journal:  Clin Dev Immunol       Date:  2012-04-02

9.  Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells.

Authors:  Haishan Li; C David Pauza
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

10.  The Role of PPARs in Placental Immunology: A Systematic Review of the Literature.

Authors:  Stefan Hutter; Julia Knabl; Ulrich Andergassen; Udo Jeschke
Journal:  PPAR Res       Date:  2013-03-10       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.